Skip to content

Bicara 制药

US · BCAX #3193 按市值排名 上市于 2024
16.78 -0.84 -4.77%
实时 - 追踪5344个代码 - 心跳于208秒前 · 2026-10-16 18:18

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了2家。
  • 机构持股总比例下降了1.2个百分点。

机构持股

机构持股比例
115.84% -1.23pp
机构数量
208 -2
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund47.26%
VC/PE Fund41.69%
Hedge Fund15.46%
Public Company10.30%
Individual/Insider1.84%
Private Company0.79%
Government Pension Fund0.15%
Insurance Company0.14%

主要股东 截至 2026-06-30

T. Rowe Price Group, Inc. 12.46% · 8.24M 股
RA Capital Management, L.P. 10.97% · 7.26M 股
Artal Group S.A. 8.47% · 5.60M 股
Biocon Limited 8.35% · 5.52M 股
Vestal Point Capital, LP 7.93% · 5.25M 股
Deep Track Capital, LP 6.20% · 4.10M 股
BlackRock 5.82% · 3.85M 股
Janus Henderson Group plc 4.79% · 3.17M 股
Red Tree Venture Capital 4.78% · 3.16M 股
TPG Capital, L.P. 4.55% · 3.01M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 10次买入 · 40次卖出

姓名职务持股比例
RA Capital Management, L.P. -- 10.97%
Kiran Mazumdar-Shaw Independent Director 0.68%
Claire Mazumdar Clemon Chief Executive Officer 0.55%
Ryan Cohlhepp President 0.27%
Ivan Hyep Chief Financial Officer 0.20%
David Raben Chief Medical Officer 0.08%
Nils Lonberg Independent Non-Executive Director 0.05%
Kathryn Haviland Independent Director 0.01%
Michael Powell Independent Chairperson --
Scott Robertson Independent Director --

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-07 Ryan Cohlhepp President Derivative Exercise and Sale -17,500 $3.79–23.43
2026-09-07 Ivan Hyep Chief Financial Officer Intent to Sell (Form 144) -12,500 $22.64
2026-08-09 Ryan Cohlhepp President Derivative Exercise and Sale -18,750 $3.79–27.98
2026-08-09 Claire Mazumdar Clemon Chief Executive Officer Derivative Exercise and Sale -10,000 $3.79–27.98
2026-08-09 Ivan Hyep Chief Financial Officer Derivative Exercise and Sale -12,500 $3.79–27.97
2026-07-27 Christy Oliger Independent Director Other Derivative Acquisition +38,950 $26.88
2026-07-27 Jeremy Bender Independent Director Other Derivative Acquisition +38,950 $26.88
2026-07-09 Claire Mazumdar Clemon Chief Executive Officer Derivative Exercise and Sale -10,000 $3.79–29.68
2026-07-08 Ryan Cohlhepp President Automatic Disposition -10,000 $28.76–30.35
2026-07-07 Ryan Cohlhepp President Derivative Exercise and Sale -18,750 $3.79–28.76
2026-07-07 David Raben Chief Medical Officer Intent to Sell (Form 144) -50,000 $28.56
2026-07-07 Ivan Hyep Chief Financial Officer Automatic Disposition -15,500 $28.60–30.31
2026-07-07 Ivan Hyep Chief Financial Officer Derivative Exercise and Sale -12,500 $3.79–28.60
2026-06-24 David Raben Chief Medical Officer Intent to Sell (Form 144) -50,000 $26.49
2026-06-08 Michael Powell Independent Chairperson Other Derivative Acquisition +19,475 $20.56
2026-06-08 Kiran Mazumdar-Shaw Independent Director Other Derivative Acquisition +19,475 $20.56
2026-06-08 RA Capital Management, L.P. -- Other Derivative Acquisition +19,475 $20.56
2026-06-08 Scott Robertson Independent Director Other Derivative Acquisition +19,475 $20.56
2026-06-08 Christopher Bowden Independent Director Other Derivative Acquisition +19,475 $20.56
2026-06-08 Kathryn Haviland Independent Director Other Derivative Acquisition +19,475 $20.56

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 18:18:37 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

Bicara 制药 讨论区 0 条评论

发表评论